Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-06-17 Capital/Financing Update
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press release: Sanofi successfully prices €1.5 billion bond issue
Capital/Financing Update Classification · 98% confidence The document is explicitly titled a "Press Release" and announces the successful pricing of a €1.5 billion bond issue (debt financing). This activity—issuing notes/bonds—falls directly under the definition of financing activities or capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not an Earnings Release (ER) as it discusses debt, not operational results, and it is not a full financial report (10-K or IR).
2025-06-17 English
SC TO-T Filing
Regulatory Filings
2025-06-17 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 98% confidence The document text is a detailed, transaction-by-transaction log, primarily in French, showing daily volumes, weighted average prices, and specific transaction details (time, quantity, price, reason for repurchase: 'MAR art.5 §2. (a)'). The presence of 'Nom du PSI' (Name of the PSI) and the nature of the data—reporting individual trades by an entity (SANOFI) involving its own shares—strongly indicates a filing related to insider transactions or share repurchase programs. The definition for Director's Dealing (DIRS) covers personal share transactions by directors, while Transaction in Own Shares (POS) covers the company buying back or selling its own shares. Since the data details transactions executed by an intermediary ('Citigroup Global Markets Europe AG') on behalf of the issuer (SANOFI) and includes a 'Raison du Rachat' (Reason for Repurchase) referencing a specific article, this aligns best with the 'Transaction in Own Shares' (POS) category, which covers share repurchase programs. If the document were solely reporting trades by directors/executives for personal benefit, DIRS would be appropriate. However, the structure suggests a mandatory disclosure of market operations related to the company's own stock management (repurchase program execution). Given the options, POS is the most precise fit for reporting the execution of share buybacks.
2025-06-16 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 98% confidence The document text consists of detailed tables showing daily transactions involving the issuer 'SANOFI' and a broker ('Citigroup Global Markets Europe AG'). The tables include columns like 'Day of the transaction', 'Total daily volume (in number of shares)', 'Price per unit', and 'Purpose of the buyback' which mentions 'MAR art.5 §2. (a)'. This structure is characteristic of regulatory filings reporting insider transactions or share repurchase activities. Specifically, the presence of 'Purpose of the buyback' and the reporting of transactions by directors/brokers strongly suggests a filing related to share transactions. The definition for 'Transaction in Own Shares' (POS) covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. This classification fits the data presented better than 'Director's Dealing' (DIRS), as the context seems focused on the company's own share movements (buybacks) rather than individual director trades, although the data format is similar to insider reporting. Given the explicit mention of buyback purpose, POS is the most appropriate fit.
2025-06-16 English
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respi
Regulatory Filings Classification · 90% confidence The document is titled "Communiqué de presse" (Press Release) and details the positive results of a Phase 4 clinical study (EVEREST) comparing Dupixent to Xolair, presented at the EAACI annual congress. It includes detailed efficacy data, safety profiles, and background information on the drugs and companies involved (Sanofi and Regeneron). This format—a formal announcement of scientific/clinical trial results, often presented at a conference—is characteristic of a press release announcing new data. Since it is not a full regulatory report (like 10-K or IR), nor a transcript of a call, nor a formal investor presentation, the most appropriate classification is a general announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best fallback for significant, non-standardized corporate announcements, although 'Earnings Release' (ER) is for financial results, and 'Investor Presentation' (IP) is for investor decks. Because this is a scientific/clinical data announcement released via press release, and it doesn't fit the specific financial report categories, RNS is the most suitable general regulatory/corporate announcement category available, though it is not a typical RNS filing. However, if we strictly adhere to the definitions, this is a press release announcing clinical data, which often falls under general corporate communications not explicitly covered. Given the context of financial reporting databases, RNS is often used for material non-financial announcements. The document length (24,847 chars) is substantial, ruling out RPA based on the 'MENU VS MEAL' rule, as it contains the substance, not just a pointer to the substance.
2025-06-15 French
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-
Earnings Release Classification · 95% confidence The document is explicitly titled '# **Press Release**' and details the presentation of new clinical trial data (EVEREST study) comparing Dupixent and Xolair at the EAACI Annual Congress. This format—a formal announcement of scientific/clinical results, often including quotes from investigators and details about the study design and outcomes—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release announcing clinical trial results and not a comprehensive financial report (10-K/IR) or a transcript of a call (CT), the most appropriate classification is Earnings Release (ER), as these often accompany or precede formal financial reporting periods to highlight key operational/product achievements. It is not a proxy statement (DEF 14A), a formal regulatory filing (RNS), or a management discussion (MDA), but a direct announcement of results. Q2 2025
2025-06-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.